Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Waldenstrom Macroglobulinemia 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

venetoclax 27Cyclophosphamide 18Azacitidine 13fludarabine 12ibrutinib 10Busulfan 10fludarabine phosphate 9Rituximab 8Mycophenolic Acid 8Methotrexate 8Cytarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Clofarabine 7Therapeutics 6Melphalan 6Antilymphocyte Serum 6obinutuzumab 5Tacrolimus 5Surveys and Questionnaires 5Stem Cell Transplantation 5Mesna 5Exercise 5Cyclosporine 5vosaroxin 4trametinib 4thymoglobulin 4ruxolitinib 4ponatinib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × CLR1404 × Other hematologic neoplasm × Clear all
NCT02952508 2026-03-18

CLOVER-WaM

Cellectar Biosciences, Inc.

Phase 2 Active not recruiting
120 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡